<DOC>
	<DOC>NCT02157090</DOC>
	<brief_summary>Recent clinical studies showed, that a hydrocolloid patch is effective, well tolerated and comparable with aciclovir cream 5 % for the treatment of HSL lesions, while affording additional benefits of wound protection, discretion and relief of social embarrassment. The aim of the actual study was the clinical assessment of the effectiveness and safety of Hansaplast® SOS Herpes Patch (HPHP) in comparison to Compeed® Herpes Vesicle Patch (CHP) in treating HSL. Both products are CE-certificated and are available at the market for medical devices.</brief_summary>
	<brief_title>Clinical Assessment of the Effectiveness and Safety of Herpes Patch SOS in the Treatment of Herpes Simplex Labialis in Comparison to a Competitor's Product.</brief_title>
	<detailed_description />
	<mesh_term>Herpes Simplex</mesh_term>
	<mesh_term>Herpes Labialis</mesh_term>
	<criteria>at least 18 years old with a history of recurrent HSL of the lips and/or perioral skin lesions typically manifesting as classical lesions duration of HSL symptoms not more than three days haven´t used acyclovir or other cold sore therapies pregnancy lactating women women of childbearing age without medically secured contraceptions topical or systemic therapy with analgesic antiinflammatory or antiviral agents within the last 2 weeks topical therapy within the treatment area systemic therapy with cytostatics or immunosuppressants</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>HSL of lips</keyword>
	<keyword>perioral skin</keyword>
	<keyword>duration of HSL symptoms not more than three days</keyword>
	<keyword>not acyclovir or other cold sore therapies</keyword>
</DOC>